Healthcare

Revenue increased 3% to $203.9 million on a reported basis, reflecting the strengthening of the Australian dollar during FY26. On a constant currency basis, revenue increased 6% to $211.5 million, which the company said demonstratedBusinessmomentum supported by growth in total trophon unit sales, expansion …

Acadia has previously indicated that the commercial launch of DAYBU in Germany is anticipated in early Q4 2026, marking the first market entry for the product following the European approval. The company noted that trofinetide is not approved for sale in Australia.

Shares closed at $0.011, the lowest price point reached over the preceding twelve-month period. This kind of price marker is commonly referenced byMarket Participantsto describe a stock's recent trading range.

The stock closed the session at $0.052, representing the lowest traded price recorded over the previous twelve months. This kind of reference point is commonly used to describe where a stock currently sits relative to its recent trading history.

Imugene Ltd (ASX:IMU) reached a new 52-week low, placing attention on the recent movement in the company’s share price. The company operates within the healthcare sector and focuses on biotechnology activities, including the development of immunotherapy-based solutions.

PainChek Ltd (ASX:PCK) reached a new 52-week low at market close on 24 August 2026, with the company’s shares trading at the lower end of their annual range. The company operates within the healthcare sector and develops digital health technology solutions focused on supporting …

Conneqt Health Ltd (ASX:CQT) reached a new 52-week low at market close on 24 August 2026, with the company’s shares trading near the lower end of their twelve-month range. The company operates within the healthcare sector, a segment that includes businesses involved in medical …